Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada

Stock Information for Revive Therapeutics Ltd

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Revive Therapeutics Ltd

Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
Revive Therapeutics Provides Corporate Update
Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110
Revive Therapeutics Explores the Use of Bucillamine for Long COVID

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.